BrainStorm to Present at Several Scientific and Investment Conferences

BrainStorm to Present at Several Scientific and Investment Conferences 
NEW YORK, NY and PETACH TIKVAH, ISRAEL -- (Marketwired) -- 04/10/13
--   BrainStorm Cell Therapeutics (OTCQB: BCLI), a leading developer
of adult stem cell technologies for neurodegenerative diseases,
announced today that the company will be presenting at several
upcoming scientific and investment conferences.  
Bizportal Biomed 2013 Conference
 On April 10th in Tel Aviv, Alon
Natanson, CEO, will make a presentation about the company's recent
scientific and business developments to institutional and life
science investors at the Bizportal Biomed 2013 Conference. 
Israstem 
On April 22nd at 10:40 a.m. in Ramat Gan, Israel, Professor Daniel
Offen, Chief Scientific Advisor, will present a Keynote Lecture
titled "Transplantation of Mesenchymal Stromal Cells Secreting
Neurotrophic Factors Shows Safety and Initial Indications of Clinical
Benefit in ALS Patients in a Phase I/II Clinical Trial" at IsraStem,
the Annual Israeli Meeting of Translational Research on Stem Cells,
Cell Therapy and Regenerative Medicine in Industry and Academia.  
ALS Canada Research Forum
 On May 4th in Toronto, Ontario, Professor
Daniel Offen, Chief Scientific Advisor, will deliver a poster
presentation about the results from the recently completed Phase I/II
clinical trial at the 9th Annual Meeting of the ALS Research Forum of
the ALS Society of Canada. 
Oppenheimer's 14th Annual Israeli Conference
 On May 12th at 13:45 in
Tel Aviv, Alon Natanson, CEO, will make a presentation about the
company's recent scientific and business developments to Israeli
financial institutions at Oppenheimer's 14th Annual Israeli
Conference. 
ALSTDI Webinar
 On May 8th at 10:00 am EST, Dr. Yael Gothelf, VP
Scientific & Regulatory Affairs, will discuss the company's clinical
trials program for NurOwn(TM) at a live webinar sponsored by the ALS
Therapy Development Institute. To register for this webinar, go to:
http://bit.ly/Zmk3ov. 
About BrainStorm Cell Therapeutics, Inc.
 BrainStorm Cell
Therapeutics Inc. is a biotechnology company engaged in the
development of first-of-its-kind adult stem cell therapies derived
from autologous bone marrow cells for the treatment of
neurodegenerative diseases. The Company holds the rights to develop
and commercialize its NurOwn technology through an exclusive,
worldwide licensing agreement with Ramot, the technology transfer
company of Tel Aviv University. For more information, visit the
company's website at www.brainstorm-cell.com. 
Safe Harbor Statement - Statements in this announcement other than
historical data and information constitute "forward-looking
statements" and involve risks and uncertainties that could cause
BrainStorm Cell Therapeutics Inc.'s actual results to differ
materially from those stated or implied by such forward-looking
statements. Terms and phrases such as "may", "should", "would",
"could", "will", "expect", "likely", "believe", "plan", "estimate",
"predict", "potential", and similar terms and phrases are intended to
identify these forward-looking statements. The potential risks and
uncertainties include, without limitation, risks associated with
BrainStorm's limited operating history, history of losses; minimal
working capital, dependence on its license to Ramot's technology;
ability to adequately protect the technology; dependence on key
executives and on its scientific consultants; ability to obtain
required regulatory approvals; and other factors detailed in
BrainStorm's annual report on Form 10-K and quarterly reports on Form
10-Q available at http://www.sec.gov. These factors should be
considered carefully, and readers should not place undue reliance on
BrainStorm's forward-looking statements. The forward-looking
statements contained in this press release are based on the beliefs,
expectations and opinions of management as of the date of this press
release. We do not assume any obligation to update forward-looking
statements to reflect actual results or assumptions if circumstances
or management's beliefs, expectations or opinions should change,
unless otherwise required by law. Although we believe that the
expectations reflected in the forward-looking statements are
reasonable, we cannot guarantee future results, levels of activity,
performance or achievements. 
CONTACTS
BrainStorm Cell Therapeutics Inc. 
Mr. Alon Natanson
CEO 
Phone: +972-3-9236384
info@brainstorm-cell.com 
www.brainstorm-cell.com 
LifeSci Advisors, LLC
Michael Rice
Founding Partner
646-597-6979
mrice@lifesciadvisors.com 
www.LifeSciAdvisors.com 
 
 
Press spacebar to pause and continue. Press esc to stop.